Roivant Sciences (ROIV) Expected to Announce Quarterly Earnings on Monday

Roivant Sciences (NASDAQ:ROIV) will likely be posting its quarterly earnings results before the market opens on Monday, February 10th. Analysts expect Roivant Sciences to post earnings of ($0.24) per share and revenue of $4.75 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Roivant Sciences Trading Down 2.1 %

ROIV opened at $11.13 on Monday. The firm has a 50 day moving average of $11.69 and a two-hundred day moving average of $11.61. The firm has a market capitalization of $8.10 billion, a PE ratio of 1.97 and a beta of 1.27. Roivant Sciences has a 12-month low of $9.69 and a 12-month high of $13.06.

Analyst Ratings Changes

ROIV has been the subject of a number of research reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.93.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the sale, the chief operating officer now directly owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction dated Monday, January 13th. The shares were acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 1,942,629 shares of company stock worth $23,034,486 in the last ninety days. Company insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.